Item 5. Other Information

During the quarter ended March 28, 2026, none of our officers or directors adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K, except as follows:

• On March 4, 2026, Shannon Parisotto, our Corporate Executive Vice President Global Discovery and Safety Assessment, entered into a Rule 10b5-1 trading arrangement for the sale of up to 16,131 shares of common stock. The arrangement’s expiration date is January 31, 2027.

• On March 6, 2026, James Foster, one of our directors, terminated a Rule 10b5-1 trading arrangement, dated March 6, 2025, for the sale of up to 168,463 shares of common stock. Mr. Foster did not sell any shares pursuant to such plan, which, absent such termination, would have expired on August 21, 2027.

• On March 6, 2026, Mr. Foster entered into a Rule 10b5-1 trading arrangement for the sale of up to 193,463 shares of common stock. The arrangement’s expiration date is June 7, 2028.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.